Investigating how a protein protects lung cells from damage caused by cigarette smoke
Decay accelerating factor (CD55) protects against lectin pathway-mediated AT2 cell dysfunction in cigarette smoke-induced emphysema
['FUNDING_R01'] · UNIVERSITY OF FLORIDA · NIH-10876318
This study is looking at how cigarette smoke harms lung cells and whether a protein called CD55 can help protect them, with the goal of finding ways to prevent lung damage in smokers and identify those at risk for conditions like emphysema and COPD.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF FLORIDA (nih funded) |
| Locations | 1 site (GAINESVILLE, UNITED STATES) |
| Trial ID | NIH-10876318 on ClinicalTrials.gov |
What this research studies
This research explores the harmful effects of cigarette smoke on lung cells and how a specific protein, decay accelerating factor (CD55), may help protect these cells from damage. The study aims to understand the mechanisms by which cigarette smoke activates the immune response in the lungs and how inhibiting certain pathways could reduce lung injury. By examining the role of CD55 in promoting the health of alveolar cells, the research seeks to develop a method for identifying individuals at risk of developing emphysema and chronic obstructive pulmonary disease (COPD). This could lead to new strategies for preventing lung damage in smokers.
Who could benefit from this research
Good fit: Ideal candidates for this research are smokers or individuals at risk of developing emphysema or COPD due to cigarette smoke exposure.
Not a fit: Patients who do not smoke and have no risk factors for emphysema or COPD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect lung cells from damage caused by cigarette smoke, potentially reducing the risk of emphysema and COPD.
How similar studies have performed: Other research has shown promise in targeting immune pathways to mitigate lung damage, suggesting that this approach could be effective.
Where this research is happening
GAINESVILLE, UNITED STATES
- UNIVERSITY OF FLORIDA — GAINESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SERBAN, KARINA — UNIVERSITY OF FLORIDA
- Study coordinator: SERBAN, KARINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.